CRDO
From Preclinical to Commercialization: A CRDO Approach to Accelerating Biologic Development
Matthias Lucke, Ph.D.; Ivonne Stelzl, Ph.D.
Coriolis Pharma
PAO-08-25-CL-02Aug 04, 2025
Developability
Streamlining Drug Development with Integrated In Silico and Laboratory Developability Assessments
Andrea Arsiccio, Ph.D.,; Eva Keilhauer, Ph.D.; Kristian Le Vay, Ph.D.
Coriolis Pharma
PAO-01-25-CL-12Jan 27, 2025
Developability
Mitigating Early Development Risks with Samsung Biologics DEVELOPICK™ Platform
Heonchang Lim
Samsung Biologics
PAO-09-24-CL-04Sep 04, 2024
IND Enablement
IND Enablement and Drug Product Development – Mitigating Risk and Accelerating through the "Valley of Death"
Johannes Clemens
Coriolis Pharma
PAO-08-24-CL-07Aug 16, 2024
Developability
Streamlining the Path to Approval with Developability and Pre-Formulation Platforms
Andrea Hawe
Coriolis Pharma
PAO-07-24-CL-11Aug 01, 2024
CRDO
Partnering with Scientific Excellence to De-Risk and Accelerate Drug Development
Silvia Steyrer-Gruber
Coriolis Pharma
PAO-07-24-CL-05Jul 16, 2024
Monoclonal Antibodies
Coriolis Pharma Launches U.S. Entity Alongside Innovative Drug Product Platform Service Offerings for Monoclonal Antibodies
Coriolis Pharma
PR-05-24-NI-02Jun 18, 2024